Olomouc

• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) Recruiting
  2025-522514-23-00 5 2026-02-12 Urinary Incontinence
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• The purpose of this study is to determine whether Tislelizumab, when given as a subcutaneous (SC) injection, reaches the same drug levels in … Recruiting
  2025-522862-58-00 5 2026-01-09 Locally advanced unresectable or metastatic gastric or gastroesophagea
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A randomized, placebo-controlled, double-blind clinical trial evaluating the safety and efficacy of parecoxib in hospitalized patients with … Recruiting
  2024-519436-17-00 4 2025-12-15 spontaneous subarachnoid hemorrhage
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• A Phase 2 trial to investigate efficacy and safety of vipoglanstat in women with endometriosis Recruiting
  2025-522452-16-00 4 2025-12-05 Endometriosis related pain
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 5 2025-11-28 Agitation Associated with Alzheimer’s Disease
• A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting
  2025-520623-24-00 7 2025-11-19 MTAP-deleted Solid Tumors
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520746-30-00 5 2025-11-18 Mild to moderate Alzheimer’s Disease
• A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co … Recruiting
  2025-520690-39-00 4 2025-11-04 Moderately to Severely Active Ulcerative Colitis (UC)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• A randomized, phase 3 multicenter study to confirm the clinical efficacy of linaprazan glurate compared to lansoprazole in participants with … Recruiting
  2024-518714-31-00 5 2025-10-03 Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• A study to investigate efficacy and safety of brivekimig in participants with Crohn’s disease Recruiting
  2024-517016-30-00 4 2025-09-26 Crohn’s disease

Showing 73–96 of 335 trials